Speaker Profile
Ph.D., Chair of Biomedical Data Science, Stanford
Biography
Sylvia Plevritis runs a research program that applies data science to the
study of cancer systems biology and patient outcomes. She is focused on
reverse engineering cell-cell interactions in the tumor microenvironment,
from single cell sequencing and multiplexed imaging platforms, in order to
identify biomarkers and drug targets and aid in treatment planning. She is
a PI with the NCI Cancer Intervention Surveillance Network, an
NCI-consortium of investigators who use simulation modeling to improve our
understanding of cancer control interventions in prevention, screening, and
treatment and their effects on population trends in cancer incidence and
mortality. These models have been used to guide public health research and
priorities, and aid in the development of optimal cancer control
strategies. She is a fellow of the American Institute for Medical and
Biological Engineering and Distinguished Investigator in the Academy of
Radiology Research, and serves on the NCI Board of Scientific Advisors
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Victor Velculescu, Johns Hopkins
PMWC Award Ceremony
• Rebecca Fitzgerald, University of Cambridge (Luminary)
• Mary-Claire King, University of Washington (Pioneer)
• Nickolas Papadopoulos, Johns Hopkins (Pioneer)
Featured Speakers
• Mary-Claire King, University of Washington
• Rebecca Fitzgerald, University of Cambridge
• Nickolas Papadopoulos, Johns Hopkins
• Victor Velculescu, Johns Hopkins
• Phil Castle, NIH
• Elad Ziv, UCSF
• Ash Alizadeh, Stanford
• Hamed Amini, Hepta
• Becky Taub, Madrigal Pharmaceuticals
• Trevor Pugh, University of Toronto
• Doga Gulhan, Harvard
• Pranav Rajpurkar, Harvard
• Chris Douville, Johns Hopkins
• Sylvia Katina Plevritis, UCSF
In Precision Medicine, Almost All Diseases Are Genetically Rare
A genetics-first keynote framing risk, prevention, and actionability.
The Reckoning
What the first wave of early detection got right and wrong.
The End of One Size Fits All
Risk-stratified screening, high-risk populations, and single-cancer tests.
Treating Disease at the Earliest Stage
Where detection and therapeutic interception begin to converge.
Pre-Cancer Detection & the Liver Disease Frontier
cfDNA and clinical action across the liver-disease-to-cancer continuum.
AI Across Multimodal Signals
Fragmentomics, methylation, imaging, pathology, and integration: hype versus real science.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
